Category Archives: CBD Supplements

The benefits of CBD and Curcumin

CBD and Curcumin – special compounds from cannabis and Turmeric

CBD is the major non-psychoactive ingredient in Cannabis and can be legally sold in the UK and every other territory we are aware of. A prominent group of compounds found called cannabidinoids (CBD), are of great benefit to the health of the human body. We’ll discuss CBD and Curcumin separately. Here’s a quick summary of the benefits of CBD.

Benefits of CBD

According to a 2013 study, it appears that CBD has anti-inflammatory, anti-convulsant, anxiolytic and antioxidant properties, ensuring it has the capacity to help treat the likes of oxidative injury, epilepsy, vomiting and nausea, neuroinflammation and anxiety1. It would take an entire book to disucss all its health uses, but here is a quick summary of what you need to know.

  • Anxiety – CBD appears possesses anxiolytic (anxiety-reducing) effects. Research published in 2012 confirms that the cannabinoid can help treat patients with social anxiety disorder and may be effective for those suffering from obsessive compulsive disorder (OCD), panic disorder and post-traumatic stress disorder2. Moreover, a study published the year before found that, among social disorder sufferers, CBD pre-treatment significantly reduced their anxiety, cognitive impairment and discomfort during a public speaking exercise3.
  • Cardiovascular health – When it comes to the health of the heart and blood vessels, CBD may help protect against vascular damage caused by consumption of high-glucose foods, inflammation and type 2 diabetes; plus, evidence suggests it can play a significant role in reducing associated vascular hyperpermeability (a cause of leaky gut in the digestive system)4.
  • Diabetes – Results from a study conducted in 2006 showed a significant reduction of diabetes among non-obese diabetic mice (diabetes occurred in just 30% of those treated with CBD, but occurred in 86% of those not treated); while treated mice also experienced considerably reduced insulitis5. Additionally, the 2005-10 National Health and Nutritional Survey – conducted on adults in the United States – discovered that marijuana-use (and, thus, consumption of CBD) was associated with 16% lower fasting insulin levels among the more then 4,500 participants6.
  • Nausea and vomiting – Cannabis has a long, centuries-long history of use in societies for helping with nausea and vomiting; among around 80 other cannabinoids, CBD has been proved by animal studies to be effective at reducing or eliminating them both (a 2012 study discovered it possessed anti-nausea and antiemetic properties when administered to rats7). 
  • Pain and inflammation – CBD may prove effective in modulating pain thanks to its ability to inhibit neuronal transmission via pain pathways; for instance, recent research found it successfully suppressed chronic inflammation and neuropathic pain in rodents8, while a 2007 study discovered that CBD was effective as a treatment for neuropathic pain among sufferers of multiple sclerosis9.
  • Seizures – A 2014 Stanford University survey into epilepsy and use of CBD-enriched cannabis saw an 84% drop in seizures among children, among whom 42% enjoyed more than an 80% reduction; the study also found further beneficial effects of CBD cannabis among sufferers, including increased alertness, improved mood and better sleep, although drowsiness and fatigue were reported as side-effects10. In the same year, another child-based study – involving sufferers of treatment-resistant epilepsy – revealed that nearly one in four (39%) of those who received an oil-based CBD extract experienced a 50% seizure reduction after three months11.
  • Other benefits – CBD is effective in modulating central nervous system (CNS) excitability and the immune system’s response to this condition12, 13, while further research suggests that it can enhance both musculoskeletal system function and joint health14. Numerous studies all extol its value in supporting the immune system.

Supplements

Liposomal CBD contain a mix of different Cannabinoids from various strains of Cannabis Sativa. The liposomal process, which is a separate subject in it’s own right, ensures a vastly higher level of absorption than most other CBD products available on the market. The extra cost is well worth it. The figure thats normally bandied around is 7-8 x better absorbed. The two products we provide both  use the same state-of-the-art, nano-particle liposomal technology – the only difference between the two being that the ‘professional strength’ is a little more concentrated, and is provided with a total of 300ml, whereas the ‘regular’ one is a total of 60ml and slightly less concentrated. Overall, the professional strength is around 20% cheaper per mg of actual CBD.

CBD-ProfessionalLiposomal CBD – Professional Strength 10 x 30ml (total of 300ml) – £319.99

Liposomal CBD (60ml) – £64.99)

What should I combine with CBD to further enhance the effects?

Obviously CBD works perfectly well by itself.  But CBD and Curcmin together are even better. So if you want to enhance the effects further, we recommend combining it with Curcumin which has some quite similar benefits to CBD, especially where is comes to supporting the immune system, cardiovascular health, reducing inflammation and helping with anxiety. (Neuro-chemical research has shown that Turmeric and Curcumin can increase Serotonin, noradrenaline and dopamine levels in the brain).

The owner of the company who manufacture the CBD and Curcumin we sell tells me he combines the two together, and this has an “amazing” effect on him. We provide two rather similar products – Liposomal Curcumin C3 Complex – 250ml which is just Curcumin and Liposomal Curcumin Turmerease – 250ml, which has a less concentrated amount of curcumin because it also contains ‘Cureit’ – which is CNTM (Complete Natural Turmeric Matrix). It’s almost impossible to say which one is better overall (they are both excellent products of course) but we have put what we hope is a helpful comparison table on both pages of the web site, which will help you decide which one to get. Obviously you can try both if you want to and see if you notice a difference between the two. If you decide to try both, we’d love to get your feedback. Write a review, and as always you’ll also get 500 reward points from us.

Further benefits of Curcumin and Turmeric (a few quick bullet points before you refuse to read any further)

  • Fights candida and other fungi
  • Good for gastrointestinal health
  • Promotes liver health

CBD and Curcumin References:

  1. Fernández-Ruiz J., Sagredo O., Pazos M. R., García C., Pertwee R., Mechoulam R. and Martínez-Orgado J. ‘Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?’. Br J Clin Pharmacol. Feb 2013; 75 (2): 323-33.
  2. Schier A. R., Ribeiro N. P., Silva A. C., Hallak J. E., Crippa J. A., Nardi A. E. and Zuardi A. W. ‘Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug’. Rev Bras Psiquiatr. Jun 2012; 34 Suppl 1: 104-10.
  3. Bergamaschi M. M. et al. ‘Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients’. Neuropsychopharmacology. May 2011; 36 (6): 1,219–1226.
  4. Stanley C. P., Hind W. H. and O’Sullivan S. E. ‘Is the cardiovascular system a therapeutic target for cannabidiol?’. Br J Clin Pharmacol. Feb 2013; 75 (2): 313-22.
  5. Weiss L., Zeira M., Reich S., Har-Noy M., Mechoulam R., Slavin S. and Gallily R. ‘Cannabidiol lowers incidence of diabetes in non-obese diabetic mice’. Autoimmunity. Mar 2006; 39 (2): 143-51.
  6. Penner E. A., Buettner H. and Mittleman, M. A. ‘The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults’. Amjmed. Jul 2013; 126 (7): 583–589.
  7. Rock E. M. et al. ‘Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus’. Br J Pharmacol. Apr 2012; 165 (8): 2,620-34.
  8. Xiong W. ‘Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors’. J Exp Med. Jun 2012; 209 (6): 1,121-34.
  9. Iskedjian M., Bereza B., Gordon A., Piwko C. and Einarson T. R. ‘Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain’. Curr Med Res Opin. Jan 2007; 23 (1): 17-24.
  10. Porter B. E. and Jacobson C. ‘Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy’. Epilepsy Behav. Dec 2013; 29 (3): 574–577.
  11. Devinsky O. et al. ‘Efficacy and safety of Epidiolex (Cannabidiol) in children and young adults with treatment-resistant epilepsy: initial data from an expanded program’. American Epilepsy Society. Abst. 3.303. 2014.
  12. Resstel L. B. et al. ‘5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats’. Br J Pharmacol. Jan 2009; 156 (1): 181-8.
  13. Costa B. et al. ‘The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain’. Eur J Pharmacol. Feb 2007; 556 (1-3): 75-83.
  14. Malfait A. M. et al. ‘The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis’. Proc Natl Acad Sci USA. Aug 2000; 97 (17): 9,561-6.

Cannabidiol Benefits: Why CBD Is Entirely Benign and Very Good For You

In many societies and communities throughout the world, marijuana and cannabis are dirty words. In one way, that’s entirely understandable. The use of cannabis oil to create marijuana as a recreational drug has been popular for decades, but is rightly heavily regulated – in many places it remains illegal – not least as it’s inevitably used as a gateway to even stronger and more dangerous drugs. However, cannabis’s use in the creation of medical marijuana – and the use of the latter – is a different kettle of fish, but no less a political and legal hot potato. For many, it’s cannabis/ marijuana full-stop and should simply be illegal; for others, although related to and associated with recreational marijuana, it’s produced for quite a different purpose and can do its users untold good and, for that reason, there should be no impediment to its legal production and consumption.

The undeniable reality – based on hard evidence – is that a prominent compound found in cannabis/ marijuana, namely cannabidiol (CBD), is of great benefit to the health of the human body; indeed, it’s proven to be able to help treat several different ailments and diseases. So much so, in fact, that nowadays CBD’s available as a naturally-derived nutritional supplement; one that’s highly recommended simply because the entirely benign and hugely beneficial nature of CBD should not – and cannot – be ignored any longer.

First things first, though; CBD has nothing to do with THD and doesn’t have the same effect on people when it’s consumed. It’s true that they’re both cannabinoids – the class of ingredients that are unique to the Cannabis sativa plant, but it’s only the infamous THD (or tetrahydrocannbinol, to call it by its full name) that has mind-altering effects in users; CBD doesn’t at all. Indeed, CBD is the major non-psychoactive ingredient in Cannabis sativa, hence its enormous suitability as the source for health-providing supplements.

But what of those health-providing properties? Well, according to a 2013 study, it appears that CBD has anti-inflammatory, anti-convulsant, anxiolytic and antioxidant properties, ensuring it has the capacity to help treat the likes of oxidative injury, epilepsy, vomiting and nausea, neuroinflammation and anxiety1.

In which case then, let’s take a closer look at some of these significant CBD health benefits…

  • Anxiety – as noted, CBD appears to possess anxiolytic (anxiety-reducing) effects. Indeed, research published in 2012 confirms that the cannabinoid can help treat patients with social anxiety disorder and may be effective for those suffering from obsessive compulsive disorder (OCD), panic disorder and post-traumatic stress disorder2.

Moreover, a study published the year before found that, among social disorder sufferers, CBD pre-treatment significantly reduced their anxiety, cognitive impairment and discomfort during a public speaking exercise3.

  • Cardiovascular health – when it comes to the health of the heart and blood vessels, it appears that CBD may help protect against vascular damage caused by consumption of high-glucose foods, inflammation and type 2 diabetes; plus, evidence suggests it can play a significant role in reducing associated vascular hyperpermeability (a cause of leaky gut in the digestive system)4.
  • Diabetes – results from a study conducted in 2006 showed a significant reduction of diabetes among non-obese diabetic mice (diabetes occurred in just 30% of those treated with CBD, but occurred in 86% of those not treated); while treated mice also experienced considerably reduced insulitis5.

Additionally, the 2005-10 National Health and Nutritional Survey – conducted on adults in the United States – discovered that marijuana-use (and, thus, consumption of CBD) was associated with 16% lower fasting insulin levels among the more then 4,500 participants6.

  • Nausea and vomiting – like it or not, cannabis has a long, centuries-long history of use in societies for treating – and, therefore, suppressing – nausea and vomiting; among around 80 other cannabinoids, CBD has been proved by animal studies to be effective at reducing or eliminating them both (a 2012 study discovered it possessed anti-nausea and antiemetic properties when administered to rats7). 

It should be noted, however, that CBD appears to behave in a diphasic fashion in this area; low doses suppress vomiting induced by toxins, while high doses appear to do the opposite or have no effect at all.

  • Pain and inflammation – as with many so-called synthetic painkillers, CBD may prove effective in modulating pain thanks to its ability to inhibit neuronal transmission via pain pathways; for instance, recent research found it successfully suppressed chronic inflammation and neuropathic pain in rodents8, while a 2007 study discovered that CBD (together with the entirely legal THC buccal spray) was effective as a treatment for neuropathic pain among sufferers of multiple sclerosis9.
  • Seizures – a 2014 Stanford University survey into epilepsy and use of CBD-enriched cannabis saw an 84% drop in seizures among children, among whom 42% enjoyed more than an 80% reduction; the study also found further beneficial effects of CBD cannabis among sufferers, including increased alertness, improved mood and better sleep, although drowsiness and fatigue were reported as side-effects10.

In the same year, another child-based study – involving sufferers of treatment-resistant epilepsy – revealed that nearly one in four (39%) of those who received an oil-based CBD extract experienced a 50% seizure reduction after three months11.

  • Other benefits – it appears that, along with other cannabinoids, CBD is effective in modulating central nervous system (CNS) excitability and the immune system’s response to this condition12, 13, while further research suggests that it can enhance both musculoskeletal system function and joint health14.

Supplements

So then, as has hopefully now been made clear, CBD in supplement form offers many important benefits for your health. To that end, you may be interested to learn that here at The Finchley Clinic we can now offer you a pair of CBD supplements that, via the dynamically advanced, liposomal nutritional-delivery process, ensure you’ll receive the greatest possible health value and support from cannabidiol:

CBD-Professional

Liposomal CBD – Professional Strength – derived from ethically sourced hemp (with a mix of sativa and indica), this supplement is the best quality, most absorbable European liposomal CBD product available; it’s said to be up to six times better absorbed than regular CBD oil containing the same amount of cannabinoids.

CBD-liposomal

Liposomal CBD (60mg) – the 60ml version of this new class of bio-available supplement; making use of state-of-the-art, nano-particle technology to ensure much higher absorption than comparative products, it offers the full spectrum of CBD via CO2 extraction.

References:

  1. Fernández-Ruiz J., Sagredo O., Pazos M. R., García C., Pertwee R., Mechoulam R. and Martínez-Orgado J. ‘Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?’. Br J Clin Pharmacol. Feb 2013; 75 (2): 323-33.
  2. Schier A. R., Ribeiro N. P., Silva A. C., Hallak J. E., Crippa J. A., Nardi A. E. and Zuardi A. W. ‘Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug’. Rev Bras Psiquiatr. Jun 2012; 34 Suppl 1: 104-10.
  3. Bergamaschi M. M. et al. ‘Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients’. Neuropsychopharmacology. May 2011; 36 (6): 1,219–1226.
  4. Stanley C. P., Hind W. H. and O’Sullivan S. E. ‘Is the cardiovascular system a therapeutic target for cannabidiol?’. Br J Clin Pharmacol. Feb 2013; 75 (2): 313-22.
  5. Weiss L., Zeira M., Reich S., Har-Noy M., Mechoulam R., Slavin S. and Gallily R. ‘Cannabidiol lowers incidence of diabetes in non-obese diabetic mice’. Autoimmunity. Mar 2006; 39 (2): 143-51.
  6. Penner E. A., Buettner H. and Mittleman, M. A. ‘The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults’. Amjmed. Jul 2013; 126 (7): 583–589.
  7. Rock E. M. et al. ‘Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus’. Br J Pharmacol. Apr 2012; 165 (8): 2,620-34.
  8. Xiong W. ‘Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors’. J Exp Med. Jun 2012; 209 (6): 1,121-34.
  9. Iskedjian M., Bereza B., Gordon A., Piwko C. and Einarson T. R. ‘Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain’. Curr Med Res Opin. Jan 2007; 23 (1): 17-24.
  10. Porter B. E. and Jacobson C. ‘Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy’. Epilepsy Behav. Dec 2013; 29 (3): 574–577.
  11. Devinsky O. et al. ‘Efficacy and safety of Epidiolex (Cannabidiol) in children and young adults with treatment-resistant epilepsy: initial data from an expanded program’. American Epilepsy Society. Abst. 3.303. 2014.
  12. Resstel L. B. et al. ‘5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats’. Br J Pharmacol. Jan 2009; 156 (1): 181-8.
  13. Costa B. et al. ‘The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain’. Eur J Pharmacol. Feb 2007; 556 (1-3): 75-83.
  14. Malfait A. M. et al. ‘The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis’. Proc Natl Acad Sci USA. Aug 2000; 97 (17): 9,561-6.